Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
IND application for EB-003 expected in early 2026
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
CRISPR-based detection enables highly specific molecular recognition
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Subscribe To Our Newsletter & Stay Updated
